These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20471890)

  • 1. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients.
    Finckh A; Dudler J; Wermelinger F; Ciurea A; Kyburz D; Gabay C; Bas S;
    Joint Bone Spine; 2010 Jul; 77(4):313-8. PubMed ID: 20471890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
    Daniel SR; McDermott JD; Le C; Pierce CA; Ziskind MA; Ellis LA
    J Med Econ; 2018 Jul; 21(7):724-731. PubMed ID: 29718743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [THE INPUT OF MEASURING INFLIXIMAB LEVELS AND LEVELS OF ANTIBODIES TO INFLIXIMAB IN THE MANAGEMENT OF PATIENTS WITH RHEUMATIC DISEASES].
    Braun-Moscovici Y; Dagan A; Toledano K; Markovits D; Saffouri A; Beshara-Garzoz R; Naffaa ME; Rozin A; Nahir MA; Balbir-Gurman A
    Harefuah; 2017 Jul; 156(7):427-430. PubMed ID: 28786280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
    Siljehult F; Ärlestig L; Eriksson C; Rantapää-Dahlqvist S
    Scand J Rheumatol; 2018 Sep; 47(5):345-350. PubMed ID: 29701536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.
    Krintel SB; Grunert VP; Hetland ML; Johansen JS; Rothfuss M; Palermo G; Essioux L; Klause U
    Rheumatology (Oxford); 2013 Jul; 52(7):1245-53. PubMed ID: 23459699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody].
    Song M; Li F; Xie X; Chen J; Tang M; Tian J; Du J; Ge Y; Li S; Xu S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Sep; 43(9):982-986. PubMed ID: 30333289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.
    Yukawa N; Fujii T; Kondo-Ishikawa S; Yoshifuji H; Kawabata D; Nojima T; Ohmura K; Usui T; Mimori T
    Arthritis Res Ther; 2011; 13(6):R213. PubMed ID: 22192852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
    Steenholdt C; Al-khalaf M; Brynskov J; Bendtzen K; Thomsen OØ; Ainsworth MA
    Inflamm Bowel Dis; 2012 Dec; 18(12):2209-17. PubMed ID: 22344964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.
    Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA
    Aliment Pharmacol Ther; 2011 Jul; 34(1):51-8. PubMed ID: 21535447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
    Radstake TR; Svenson M; Eijsbouts AM; van den Hoogen FH; Enevold C; van Riel PL; Bendtzen K
    Ann Rheum Dis; 2009 Nov; 68(11):1739-45. PubMed ID: 19019895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis.
    Takasugi K; Nishida K; Natsumeda M; Yamashita M; Yamamoto W; Ezawa K
    Mod Rheumatol; 2018 May; 28(3):452-460. PubMed ID: 28828944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis.
    Kimura K; Takayanagi R; Yokoyama H; Yamada Y
    Rheumatol Int; 2012 Jan; 32(1):145-50. PubMed ID: 20680285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
    Nanda KS; Cheifetz AS; Moss AC
    Am J Gastroenterol; 2013 Jan; 108(1):40-7; quiz 48. PubMed ID: 23147525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
    Svenson M; Geborek P; Saxne T; Bendtzen K
    Rheumatology (Oxford); 2007 Dec; 46(12):1828-34. PubMed ID: 18032541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
    Am J Gastroenterol; 2014 Jul; 109(7):1055-64. PubMed ID: 24796769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.
    Corstjens PL; Fidder HH; Wiesmeijer KC; de Dood CJ; Rispens T; Wolbink GJ; Hommes DW; Tanke HJ
    Anal Bioanal Chem; 2013 Sep; 405(23):7367-75. PubMed ID: 23836086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A; Simard JF; Gabay C; Guerne PA;
    Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
    Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.